Rayno Biopharmaceutical Portfolio Performance- After Sell-Off 2/26/13
Caution-Follow Technicals-Potential for Macro Risk Off The Life Science sector is about 2% off highs of February 1 and has formed a double top from October 5 highs. In recent posts we urged caution as some MO stocks had blow-off tops (ALXN,MDVN, REGN) and the IBB and XBI were unable to reach...
Rayno Life Science Tools and DX: Genomic Health (GHDX $28.80) Added
Genomic Health-Good Long Term Value This looks like a good entry point for buying shares of Genomic Health (GHDX $28.50), a molecular diagnostic company focused on personalized medicine for cancer with its oncotype DX invasive breast cancer test.Yesterday the Company announced results from next...
Biotech Stocks Rally After Brief Sell-Off: INFI, PCYC Update-1 2/25
Technicals Still Rule As Momentum Eases-Reiterate Caution MO favs down: INFI, MDVN, PCYC The Life Science sector is up about 1% after two days of selling on heavy volume. The bellwether ETFs (IBB $145.16) are about 2% off 52 week highs and we do not expect this rally to surpass highs so...
MO Money Moves On to Infinity Pharmaceuticals (INFI $41.10)Up 16%
The BIG money in biotech has moved on to new names like Infinity (INFI) up 15 points since December. In the meantime they are moving out of the big winners from 2012 like Alexion (ALXN $83.4) down 3% and Regeneron (REGN $160) down 2.7% . See previous postings. The tremendous liquidity in this...
Big Money and Celebrity Financial News: Icahn Effect Redux
The Stock Market Realty Shows In case you missed it stocks lately are being driven by hedge funds and celebrity billionaires who tout their positions. The Icahn vs Ackman drama is the latest high profile realty show featured mainly by CNBC-TV. Biotechnology stocks have always been driven by a...